Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$45 Mln
P/E Ratio
--
P/B Ratio
0.27
Industry P/E
--
Debt to Equity
0.3
ROE
-0.73 %
ROCE
-57.11 %
Div. Yield
0 %
Book Value
2.04
EPS
-1.6
CFO
$-116.66 Mln
EBITDA
$-393.58 Mln
Net Profit
$-664.07 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Century Therapeutics Inc (IPSC)
| -50.09 | -1.72 | -40.34 | -82.50 | -65.27 | -- | -- |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Century Therapeutics Inc (IPSC)
| -69.28 | -35.28 | -67.65 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101,... an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. Address: 25 North 38th Street, Philadelphia, PA, United States, 19104 Read more
COO & Head of Early Development
Dr. Adrienne Farid Ph.D.
COO & Head of Early Development
Dr. Adrienne Farid Ph.D.
Headquarters
Philadelphia, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Century Therapeutics Inc (IPSC) stood at $ 353 Mln as on 31-Dec-24
The share price of Century Therapeutics Inc (IPSC) is $0.50 (NASDAQ) as of 29-Apr-2025 16:22 EDT. Century Therapeutics Inc (IPSC) has given a return of -65.27% in the last 3 years.
Century Therapeutics Inc (IPSC) has a market capitalisation of $ 45 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Century Therapeutics Inc (IPSC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Century Therapeutics Inc (IPSC) and enter the required number of quantities and click on buy to purchase the shares of Century Therapeutics Inc (IPSC).
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. Address: 25 North 38th Street, Philadelphia, PA, United States, 19104
The CEO & director of Dr. Adrienne Farid Ph.D.. is Century Therapeutics Inc (IPSC), and CFO & Sr. VP is Dr. Adrienne Farid Ph.D..
There is no promoter pledging in Century Therapeutics Inc (IPSC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Century Therapeutics Inc (IPSC) | Ratios |
|---|---|
|
Return on equity(%)
|
-73.14
|
|
Operating margin(%)
|
-1893.7
|
|
Net Margin(%)
|
-1920.87
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Century Therapeutics Inc (IPSC) was $0 Mln.
$0.01
(
